Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
11 evidence topics · 10 sources
Summary
In the Sequenced Treatment Alternatives to Relieve Depression trial, remission rates fell from 36.8% at step 1 to 13.0% at step 4, with higher relapse rates after more steps, and a reanalysis with the protocol-stipulated HRSD found a cumulative remission rate of 35.0% against the reported 67%. ICER's draft scope states that another antidepressant course succeeds much less often in TRD. Adjunctive atypical antipsychotics have a “greater side effect burden than antidepressant monotherapy”: one analysis reported akathisia with aripiprazole (NNH 4) and sedation with quetiapine (NNH 3), and one study found higher all-cause mortality with antipsychotic use (HR 1.21). Esketamine is dispensed and administered only in certified healthcare settings, with monitoring for at least 2 hours at each session, and ketamine and esketamine often require repeated visits for maintenance doses and have limited access in some regions. In one analysis, ketamine effects lasted no more than one week. After successful ECT, 51.1% of patients relapsed by 12 months on continuation pharmacotherapy, and ECT use is limited by stigma, general anaesthesia, and concern about cognitive effects. rTMS requires daily clinic visits, psychotherapy can be burdensome because of frequent visits, and access is limited because not all providers have adequate training, and VNS carries a greater than 5% chance of significant adverse events.
Diminishing remission with each successive treatment step
“The QIDS-SR(16) remission rates were 36.8%, 30.6%, 13.7%, and 13.0% for the first, second, third, and fourth acute treatment steps, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, those who required more treatment steps had higher relapse rates during the naturalistic follow-up phase.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When more treatment steps are required, lower acute remission rates (especially in the third and fourth treatment steps) and higher relapse rates during the follow-up phase are to be expected.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Reanalysis of cumulative remission in the Sequenced Treatment Alternatives to Relieve Depression trial
“In contrast to the STAR*D-reported 67% cumulative remission rate after up to four antidepressant treatment trials, the rate was 35.0% when using the protocol-stipulated HRSD and inclusion in data analysis criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tolerability of adjunctive antipsychotics
“Adjunctive strategies, especially with atypical antipsychotic agents (serotonin and dopamine activity modulators), have greater evidence for efficacy and shorter time to response or remission, but they generally have a greater side effect burden than antidepressant monotherapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, antipsychotic users had increased risk of all-cause mortality (hazard ratio 1.21; 95% CI 1.07-1.33).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These findings do not support the use of antipsychotic augmentation in patients with treatment-resistant depression.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Esketamine: certified settings and two-hour observation at each session
Ketamine and esketamine: treatment space, repeated visits, and regional access
ECT: stigma, anaesthesia, cognitive effects, and relapse
“However, the clinical use of ECT is often hindered by stigma, the need for general anaesthesia, concern about cognitive adverse effects, and high rates of relapse after acute treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Neuromodulation: availability, daily visits, and specialized personnel
“because of feasibility issues, including limited availability (especially in the public health sector), patient burden (e.g., requiring daily clinic visits for rTMS), and the need for specialized personnel (e.g., anaesthesiologists for ECT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote